We are working in conjunction with Nanobeak, Inc. (Licensor) who executed a non-exclusive sub-license with us to enable us to market a narcotic detection sensor they are developing in collaboration with NASA. Our sub-license expires on December 31, 2021.
Our products will be regulated by numerous governmental authorities, principally the U.S Food and Drug Administration (FDA), as well as state and foreign regulatory agencies. There can be no assurance that the FDA will provide marketing clearance for the device.
There are currently a variety of breathalyzer smartphone apps which essentially focus on alcohol detection. We are collaborating with Licensor to market devices to screen for a variety of narcotics both legal and illicit. Making up the narcotic detection space are both domestic and international organizations that range from small, privately held companies to larger companies that include an array of narcotics screening solutions. Because toxicology screens are the most common types of narcotic testing products on the market, we believe that advanced technology that detects discrete drug levels in an individual’s system through exhalation will assist this market to expand.
Nano Mobile Healthcare sensor will screen for the Volatile Organic Compound signatures in a person’s breath. Our device and application (working with any smart phone, laptop or tablet) will be able to identify the presence of narcotics from a single exhalation. Results will be able to be viewed by the end user in real time.
We outsource all of our non-executive functions to our Licensor.
Company contact information
One Boston Place, Suite 2600 Boston MA, 62108 Phone +1-617-336-7001
The current version of the narcotics detection sensor is pictured below however its form may change prior to marketing
The components of the narcotics detection sensor are shown below
Thu 4/20/2017 3:04 PM "we are working diligently to get our filings current, as well as to move forward with news" VNTH President J. Peters
(via an investor's email inquiry & quoted response)
Directors and Officers
Joe Peters - Chairman of the Board and CEO: Age: 58 Education: West Scranton High School, 1975; bachelor’s degree, criminal justice, King’s College, 1979; juris doctor, Dickinson School of Law, 1983 Experience: Scranton police officer, 1978-1981; assistant, deputy and executive deputy attorney general with focus on organized crime and drugs, including as director of the Bureau of Narcotics Investigation, attorney general’s office, 1982-1998; director, federal high-intensity drug-tracking area, Philadelphia, 1998-1999; director, all federal high-intensity drug-trafficking areas, national drug czar’s office, 1999-2003; counterterrorism consultant, 2004-present; president and chief executive officer, Nano Mobile Healthcare Inc., 2014-present; president, MSGI Technology Solutions, Inc. (formerly, MSGI Security Solutions, Inc., Media Services Group), 2004-present; executive director, Scranton Cultural Center, 2011-2013; state executive deputy attorney general in charge of communications, 2013-2014.
Robert Chicoski - Director and CFO: Since 2004 Mr. Chicoski has been the acting CFO for two Boston-based businesses providing contract CFO services for all accounting, finance, tax and bank financing matters as well as other strategic business and corporate matters. From June 2012 through April 2017, Mr. Chicoski was the controller, acting Chief Financial Officer and Private Investor Mentor for GVP Global Corp, a Boston private equity investment company. Mr. Chicoski has been a Certified Public accountant since 1969. He was the founder, Treasurer and Chief Financial Officer of a start- up company, World Energy Solutions, that was previously listed on the Over the Counter Exchange as XWES and subsequently acquired by EnerNOC in 2015. Mr. Chicoski received a BS in Accounting from Bentley College of Accounting and Finance.
James C. Katzaroff Director: The founder of Advanced Medical Isotope Corp. (Symbol: ADMD) and was the Chief Executive Officer from 2007 through December 2016. Mr. Katzaroff continues to serve as a director of ADMD. ADMD is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non-resectable tumors. Mr. Katzaroff holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara and has completed advanced management courses at the University of Washington.
John Groman is the largest investor in Nano Mobile Healthcare Inc. He is a graduate of Yale and Harvard Business School. He started investing in Nano Mobile Healthcare in 2013.